N-Acetyl Cysteine (NAC) for PCOS (Polycystic Ovary Syndrome)

NAC is one of the better-supported supplements in PCOS, and unusually the comparison in the literature is not against placebo alone but against metformin — the standard insulin-sensitising drug for the condition. Several trials found NAC comparable on ovulation and pregnancy rates, with fewer gastrointestinal complaints. That makes it a genuine option rather than an adjunct curiosity, particularly for women who cannot tolerate metformin.

The effects reported are on ovulation rate, clomiphene response, insulin sensitivity and testosterone, with meta-analytic support for improved pregnancy and ovulation rates versus placebo. Effects on cycle regularity and hirsutism are less consistent and take longer. Most of the trials are relatively small and several come from a handful of centres, so the effect size should be treated as provisional even though the direction is consistent.

NAC is a cysteine donor and therefore a rate-limiting precursor for glutathione, the body's principal intracellular antioxidant. PCOS involves measurably elevated oxidative stress in follicular fluid and serum, and that oxidative environment impairs oocyte quality and granulosa cell function.

On the metabolic side, NAC improves insulin receptor signalling and reduces the oxidative-stress-driven serine phosphorylation of insulin receptor substrate proteins that contributes to insulin resistance. Lower circulating insulin reduces ovarian theca cell androgen production and raises sex hormone binding globulin, which lowers free testosterone — the route by which insulin sensitisation improves the hyperandrogenic features of PCOS. NAC also has anti-inflammatory activity through NF-kB inhibition, relevant to the chronic low-grade inflammation characteristic of the condition.

Fertility trials typically used 1.2 g daily in divided doses, often timed with a clomiphene cycle; general metabolic protocols use 1.8 g daily. Take with food — nausea on an empty stomach is the main reason people stop.

The linked systematic review and meta-analysis in Obstetrics and Gynecology International pooled randomised controlled trials of NAC in PCOS and found significantly improved pregnancy and ovulation rates compared with placebo. The comparison against metformin was the more clinically interesting finding: the two were broadly similar on reproductive endpoints, with NAC better tolerated. The review also flagged the limitations honestly — modest sample sizes, variable dosing, inconsistent PCOS diagnostic criteria across trials, and clustering of studies by centre. That is why the verdict here is likely rather than strong: the direction of effect is consistent, the precision is not yet.

NAC has decades of clinical use at far higher intravenous doses for paracetamol overdose, and the oral safety profile at supplement doses is good. Nausea, heartburn, diarrhoea and a sulphurous smell are the usual complaints, mostly mitigated by taking capsules with food.

The interactions that matter are additive glucose lowering, mild antiplatelet activity, and nitrate potentiation — none common, all worth knowing before combining.